RxDoctor Payments Data

Francisco Cruz, MD

Nephrology · New Orleans, LANPI 1497714133

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.3% of the total across 302 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by Amgen at 24.3% of the total.

$6,135in general payments, 2019–2025

Across 302 payments — averaging $20.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$977
  • Novo Nordisk$355
  • Calliditas Therapeutics US Inc.$347
  • Bayer$327
  • Fresenius USA Marketing, Inc.$260
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$5,90696%
  • Education$2294%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,135 in reported general payments places this provider in the 75th percentile of 206 nephrology providers in Louisiana.

See all nephrology providers in Louisiana

Medicare billing

Part B allowed, 2024
$85,619
Medicare patients
152
Services billed
531

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin99$97,538
FarxigaDapagliflozin Propanediol48$48,510
KerendiaFinerenone21$25,147
LokelmaSodium Zirconium Cyclosilicate16$13,350
Repatha SureclickEvolocumab18$12,239
ProcritEpoetin Alfa16$7,121
Sevelamer Carbonate25$5,871
Testosterone16$2,355
Nifedipine ErNifedipine116$2,153
RetacritEpoetin Alfa-Epbx14$2,120
Potassium Citrate ErPotassium Citrate21$2,011
Losartan Potassium197$938
Carvedilol102$770
Cinacalcet Hcl16$723
Famotidine50$718

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$121$97,53899 claims
AstraZenecaFarxiga, Lokelma$977$61,85964 claims
BayerKerendia$327$25,14721 claims
Johnson & JohnsonProcrit$13$7,12116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 206 nephrology providers in Louisiana.

Other nephrology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →